General Information of Drug (ID: DMHV75N)

Drug Name
PMID28460551-Compound-1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Patented [1]
Colon cancer 2B90.Z Patented [1]
Colorectal cancer 2B91.Z Patented [1]
Gastric adenocarcinoma 2B72 Patented [1]
Lung cancer 2C25.0 Patented [1]
Pancreatic cancer 2C10 Patented [1]
Prostate cancer 2C82.0 Patented [1]
Cross-matching ID
PubChem CID
25190990
CAS Number
CAS 1129403-56-0
TTD Drug ID
DMHV75N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [2]
Ripretinib DM958QB Gastrointestinal stromal tumour 2B5B Approved [3]
Olaratumab DMNYOIX Soft tissue sarcoma 2B57 Approved [4]
Avapritinib DMK2GZX Gastrointestinal stromal tumour 2B5B Approved [5]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [7]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
MP470 DMELUAK Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
MEDI-575 DMI9WVM Glioblastoma multiforme 2A00.0 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Inhibitor [1]

References

1 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
2 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
7 The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
8 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
9 National Cancer Institute Drug Dictionary (drug id 452042).
10 Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
11 Clinical pipeline report, company report or official report of MedImmune (2011).